Patents Represented by Attorney Louis C. Cullman
-
Patent number: 7371228Abstract: A method and device for the treatment of an aneurysm are provided. Different therapeutic agents are delivered to the aneurysmal site by a reservoir and delivery means in a localized, and, in some embodiments, time-released regimen, to treat, limit and reduce the severity of the aneurysm.Type: GrantFiled: September 19, 2003Date of Patent: May 13, 2008Assignee: Medtronic Vascular, Inc.Inventors: Jack Chu, Dave Erickson, Prema Ganesan, Jonathan Morris
-
Patent number: 7002002Abstract: Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid, amino acid, or DNA sequences. As the vaccines may comprise different combinations of the extracellular products, subunits thereof, or encoding nucleic acids, a broad range of effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.Type: GrantFiled: September 14, 2001Date of Patent: February 21, 2006Assignee: The Regents of The University of CaliforniaInventors: Marcus A. Horwitz, Günter Harth
-
Patent number: 6849735Abstract: An improved method of synthesis of a 9-substituted hypoxanthine derivative comprises the steps of: (1) reacting aminocyanacetamide with triethyl orthoformate to form an imidoester derivative of aminocyanacetamide; (2) forming a compound having a reactive amino group on a hydrocarbyl moiety, the hydrocarbyl moiety being linked through an amide group to a physiologically active moiety or an esterified derivative of a physiologically active moiety including therein an esterified benzoyl group; (3) reacting the imidoester with the compound having the reactive amino group on the hydrocarbyl moiety to form a derivative of aminoimidazole-4-carboxamide substituted at the 1-position with a hydrocarbyl moiety linked through an amide group to a physiologically active moiety including therein an optionally esterified benzoyl group; (4) forming the six-membered heterocyclic ring of the purine moiety of the hypoxanthine by reacting the derivative of 5-aminoimidazole-4-carboxamide formed in step (3) with triethyl orthoformaType: GrantFiled: June 23, 2000Date of Patent: February 1, 2005Assignee: Merck Eprova AGInventors: Alvin J. Glasky, Heinrich Bollinger, Hans Rudolf Müller
-
Patent number: 6818439Abstract: Methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the step of administering to a human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 105 cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of the human.Type: GrantFiled: December 30, 1997Date of Patent: November 16, 2004Assignee: Chiron CorporationInventors: Douglas J. Jolly, Stephen Chang, James G. Respess, Nicholas J. DePolo, David Chi-Tang Hsu, Carlos E. Ibanez, Judith Greengard, Lee Will
-
Patent number: 6818223Abstract: Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid or DNA sequences. As the vaccines may comprise different combinations of the extracellular products, subunits thereof, or encoding nucleic acids, a broad range of effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.Type: GrantFiled: September 14, 2001Date of Patent: November 16, 2004Assignee: The Regents of the University of CaliforniaInventors: Marcus A. Horwitz, Günter Harth
-
Patent number: 6797266Abstract: Probiotic compositions are provided that comprise Lactobacillus casei strain KE01 having ATCC accession number PTA-3945. The disclosed probiotic compositions are useful in inhibiting enteric pathogen diseases in animals and in maintaining animal health. Methods of making and using Lactobacillus casei strain KE01 probiotic compositions are also disclosed as are methods of using these probiotic compositions.Type: GrantFiled: December 17, 2001Date of Patent: September 28, 2004Assignee: ProbiohealthInventor: A. Satyanarayan Naidu
-
Patent number: 6783947Abstract: Alpha-haloketones are useful alkylating agents for coupling to sulfhydryl-containing biomolecules. However, they react spontaneously with water, alkali and organic bases and therefore cannot be stored for extended periods of time in aqueous solutions, particularly in the presence of proteins at physiological pH. The present invention provides novel solutions to these problems, however, as novel compounds and compositions comprising protected haloketones are disclosed herein. Methods of preparing and using protected haloketones which are useful in a variety of applications—e.g., in assays and conjugation reactions—are also disclosed herein.Type: GrantFiled: September 9, 1999Date of Patent: August 31, 2004Assignee: Dade Behring Marburg GmbHInventors: Steve de Keczer, Yen Ping Liu, Dariush Davalian, Nurith Kurn, Edwin F. Ullman
-
Patent number: 6770638Abstract: Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.Type: GrantFiled: July 30, 2002Date of Patent: August 3, 2004Assignee: Spectrum Pharmaceuticals, Inc.Inventors: David B. Fick, Mark M. Foreman, Alvin J. Glasky, David R. Helton
-
Patent number: 6761894Abstract: Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid or DNA sequences. As the vaccines may comprise different combinations of the extracellular products or encoding nucleic acids, a broad range effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.Type: GrantFiled: May 23, 1995Date of Patent: July 13, 2004Assignee: The Regents of the University of CaliforniaInventor: Marcus A. Horwitz
-
Patent number: 6759427Abstract: A tetrahydroindolone derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring. The moiety A can be a tetrahydroindolone moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.Type: GrantFiled: April 20, 2001Date of Patent: July 6, 2004Assignee: Spectrum Pharmaceuticals, Inc.Inventors: David B. Fick, Mark M. Foreman, Alvin J. Glasky
-
Patent number: 6758896Abstract: Clinkered materials containing high concentrations of {(C,K,N,M)4 (A,F,Mn,P,T,S)3 Cl,{overscore (S)})}(crystal X), and {C2S)3(C{overscore (S)})3Ca(f,Cl)2} or C9S3{overscore (S)}3Ca(f,cl)2 crystal Y), and/or {C5S2{overscore (S)}) (crystal Z) directly from the kiln, rapidly hardening ultra-high early strength cement including these clinkered materials, methods for forming and using said compositions and the cements so produced are claimed. The methods include the steps of forming a mixture of raw material containing CaO, MgO, Al2O3, Fe2O3, TiO2, Mn2O5, SiO2, SO3, Na2O, K2O, P2O5 and F, respectively designated C, M, A, F, T, Mn, S, {overscore (S)}, N, K, P and f, and heating said mixture to an elevated temperature between 900° C. and 1,200° C.; before determining average amount of crystals X, Y, and Z.Type: GrantFiled: July 18, 2001Date of Patent: July 6, 2004Inventor: Hassan Kunbargi
-
Patent number: 6752993Abstract: Vaccines based on majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. In addition to other infectious agents, the vaccines-so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.Type: GrantFiled: November 23, 1993Date of Patent: June 22, 2004Assignee: The Regents of the University of CaliforniaInventor: Marcus A. Horwitz
-
Patent number: 6750056Abstract: Metal binding proteins, associated compositions and methods for their production and use are disclosed. The metal binding proteins include have amino acid sequences analogous to at least one metal binding protein, and conservative amino acid substitutions thereof from a brine shrimp (Artemia). Also provided are the associated nucleic acid sequences encoding metal binding proteins.Type: GrantFiled: September 6, 2001Date of Patent: June 15, 2004Inventors: Roger A. Acey, Michael Mustillo, Brenton G. Harpham
-
Patent number: 6730512Abstract: The present invention provides to immunogene therapy protocols for the treatment of tumors. In particular, the present invention provides combinations of immune-modulating proteins that induce systemic immunity against tumors. In addition, the present invention provides humanized animal models suitable for the evaluation of anti-human tumor immunity and permit the identification of combinations of immune-modulating genes which when delivered to human tumor cells induce an effective anti-tumor response, including a systemic anti-tumor response.Type: GrantFiled: April 4, 2001Date of Patent: May 4, 2004Assignee: Amdl, Inc.Inventor: Lung-Ji Chang
-
Patent number: 6703046Abstract: Extremely hydrophobic nitric oxide (NO) releasing polymers are disclosed. The extremely hydrophobic NO-releasing polymers provided are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. These polymers can be loaded with extremely high NO levels and designed to release NO in manners than mimic natural biological systems. The NO-releasing extremely hydrophobic polymers provided can maintain a sustained NO release for periods exceeding nine months. Also provided are related medical devices made using these NO-releasing extremely hydrophobic polymers.Type: GrantFiled: October 4, 2001Date of Patent: March 9, 2004Assignees: Medtronic AVE Inc., United States of AmericaInventors: Anthony L. Fitzhugh, Robert Cafferata, Larry K. Keefer
-
Patent number: 6667151Abstract: Anti-lentivirus vaccines and immunotherapeutics and methods for preparing and using same are disclosed. The vaccines and immunotherapeutics are produced using non-immunosuppressive lentivirus trans-activator of transcription (Tat) proteins. An associated in vitro ultra-sensitive macrophage Tat bioassay is disclosed for assessing the immunosuppressive qualities of the lentivirus Tat preparations of the present invention. Additionally, a related long-term T4 cell propagation system for characterizing lentivirus Tat is also disclosed. The present invention has additional utility in the treatment and prevention of AIDS.Type: GrantFiled: August 10, 2000Date of Patent: December 23, 2003Assignee: InIst, Inc.Inventor: David I. Cohen
-
Patent number: 6645518Abstract: Methods are provided for delivering nitric oxide to the vascular tissue of a patient to inhibit or prevent restenosis or improve vascular function following various surgical procedures or associated with various NO-related conditions. The disclosed methods comprise contacting the vascular tissue of a patient with a medical device coated with a coating comprising nitric oxide associated with and releaseable from a polyurea network formed from the reaction on said medical device of a polyisocyanate; an amine donor and/or hydroxyl donor; an isocyanatosilane adduct having terminal isocyanate groups and at least one hydrolyzable alkoxy group bonded to silicon; and optionally a polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid.Type: GrantFiled: April 30, 2002Date of Patent: November 11, 2003Inventors: Eugene Tedeschi, Chirag B. Shah
-
Patent number: 6630490Abstract: A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.Type: GrantFiled: July 6, 2001Date of Patent: October 7, 2003Assignee: NeoTherapeutics, Inc.Inventors: Jack Diamond, Alvin J. Glasky
-
Patent number: 6630478Abstract: A method of treating drug-induced peripheral neuropathy comprising administering to a patient with drug-induced peripheral neuropathy an effective quantity of N-4-carboxaphenyl-3-(6-oxohydropurin-9-yl)propananide AIT-082, is disclosed. Peripheral nerve sprouting can be induced through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy is associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine.Type: GrantFiled: July 6, 2001Date of Patent: October 7, 2003Assignee: NeoTherapeutics, Inc.Inventors: Jack Diamond, Alvin J. Glasky, Mark M. Foreman
-
Patent number: 6599510Abstract: Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid, amino acid, or DNA sequences. As the vaccines may comprise different combinations of the extracellular products, subunits thereof, or encoding nucleic acids, a broad range of effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.Type: GrantFiled: September 21, 1998Date of Patent: July 29, 2003Assignee: The Regents of the University of CaliforniaInventors: Marcus A. Horwitz, Günter Harth